Literature DB >> 31726450

Which Patients Require Physician-Led Inter-Hospital Transport in View of Endovascular Therapy?

Franck Leibinger1, Denis Sablot2,3, Laurène Van Damme4, Nicolas Gaillard4,5, Ludovic Nguyen Them4, Marlène Lachcar6, Nathalie Duchateau6, Caroline Arquizan5, Geoffroy Farouil7, Majo Ibanez4, Céline Pujol6, Bénédicte Fadat4, Thibaut Allou4, Francis Coll6, Laurent Benayoun1, Julie Mas4, Philippe Smadja7, Adelaïde Ferraro-Allou4, Isabelle Mourand5, Anais Dutray4, Maxime Tardieu7, Snejana Jurici4, Jean-Marie Bonnec6, Nadège Olivier4, Sandra Cardini7, Sabine Aptel7, Ana-Maria Marquez7, Adrian Dumitrana4, Vincent Costalat8, Alain Bonafe7,8.   

Abstract

INTRODUCTION: The current guidelines advocate the implementation of stroke networks to organize endovascular treatment (ET) for patients with acute ischemic stroke due to large vessel occlusion (LVO) after transfer from a Primary Stroke Centre (PSC) to a Comprehensive Stroke Centre (CSC). In France and in many other countries around the world, these transfers are carried out by a physician-led mobile medical team. However, with the recent broadening of ET indications, their availability is becoming more and more critical. Here, we retrospectively analysed data of patients transferred from a PSC to a CSC for potential ET to identify predictive factors of major complications (MC) at departure and during transport that absolutely require the presence of a physician during interhospital transfer.
METHODS: This observational, single-centre study included patients with evidence of intracranial LVO transferred for ET from Perpignan to a 156 km-distant CSC between January 1, 2015 and -December 31, 2018. We compared 2 groups: MC group (patients who required emergency intervention by the medical team due to life-threatening complications, including need of mechanical ventilation at departure) and non-MC group (all other patients who experienced no or only minor complications that could be managed by the emergency paramedics alone).
RESULTS: Among the 253 patients who were transferred to the CSC, 185 (73.1%) had no complication, 57 (22.6%) minor complications, and 11 (4.3%) had MC. In multivariate analysis, MC was associated with basilar artery (BA) occlusion (p < 0.0001), initial National Institute of Health Stroke Scale (NIHSS) score >22 (p < 0.005), and history of atrial fibrillation (p < 0.04). Among the 168 patients treated with intravenous thrombolysis (IVT), only 1 patient (0.6%) had MC due to an IVT-related adverse event during transfer.
CONCLUSIONS: Physician-led inter-hospital transports are warranted for patients with BA occlusion, initial NIHSS score >22, or history of atrial fibrillation. For the other patients, transfer without a physician may be considered, even if treated with IVT.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Adverse event; Ischemic stroke; Reperfusion; Stroke management; Thrombectomy

Mesh:

Year:  2019        PMID: 31726450     DOI: 10.1159/000504314

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  3 in total

1.  National implementation of reperfusion for acute ischaemic stroke in England: How should services be configured? A modelling study.

Authors:  Michael Allen; Kerry Pearn; Gary A Ford; Phil White; Anthony G Rudd; Peter McMeekin; Ken Stein; Martin James
Journal:  Eur Stroke J       Date:  2021-12-23

2.  [Appropriate allocation of resources for interhospital transfer in emergency medical service-is a physician in the dispatch center helpful?]

Authors:  H Schröder; A-K Brockert; S K Beckers; A Follmann; A Sommer; F Kork; R Rossaint; M Felzen
Journal:  Anaesthesist       Date:  2020-07-15       Impact factor: 1.041

3.  Safety of inter-hospital transfer of patients with acute ischemic stroke for evaluation of endovascular thrombectomy.

Authors:  Lars-Peder Pallesen; Simon Winzer; Kristian Barlinn; Alexandra Prakapenia; Timo Siepmann; Cosima Gruener; Johannes Gerber; Kevin Haedrich; Jennifer Linn; Jessica Barlinn; Volker Puetz
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.